India?s Current Status Of Pharmaceutical Biotechnology | 17145
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

India?s current status of pharmaceutical biotechnology

5th World Congress on Biotechnology

Govindasamy Agoramoorthy

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.S1.027

India?s biotechnology industry is moving towards new heights keeping with the pace of global development. The center of concentration of India?s biotech industry is biopharmaceuticals since India is one among the global manufacturers of generic drugs. As a result, Indian companies are increasingly under pressure to join the bandwagon of the biopharmaceutical global market, and the biopharmaceutical segment alone has contributed 77% of the total biotech market between 2005 and 2006. India is steadily increasing its efforts to become a global player in biotech activities and investments supported by manpower, knowledge, biodiversity and technology.In1986, the Department of Biotechnology was created with an investment of USD 210 million to support several research institutions across India. India ranks among the top 12 nations in the long list of biotech companies employing about 20,000 people with a global market contribution of 2%. Among the biotech industry, healthcare sector dominates (60%), followed by service sector (25%) and agricultural biotech (15%). This presentation will highlight the contributions of the India?s biotech industry with respect to biopharmaceutical and healthcare with an emphasis on the achievements of different segments of biopharmaceutical and healthcare sectors such as therapeutics, diagnostics, stem cell research, healthcare related bioinformatics and animal health care.
Govindasamy Agoramoorthy has been serving as Distinguished Research Professor at the College of Pharmacy and Health Care, Tajen University, Taiwan over the last decade. His research ranges from biotechnology to sustainable development, and he has carried out field research in Asia, Africa, and South America over the last 25 years. He serves in the editorial board of several international peer-reviewed journals including Current Biotechnology (Bentham Science), Journal for Nature Conservation (Elsevier), Journal of Applied Animal Welfare Sciences (Taylor & Francis), Journal of Environmental Biology (Triveni), etc. Between 1989 and 1993, he served as Visiting Scientist at Smithsonian Institution (Washington, DC). Over the last decade, he has been involved in integrated multidisciplinary research involving environment, human health, natural medicine, biotechnology, bioinformatics, biological sciences and social sciences. He is currently Tata Visiting Chair in India. Professor Agoramoorthy authored 25 books, 60 book chapters, and 200 scientific articles in peer-reviewed journals with impact factor.